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Introduction
A child's development generally proceeds along expected pathways, with anticipated levels of function for specific ages. When these levels are not met, the treating physician must determine whether the child has a static or a progressive process. If the child achieves certain levels of development, then loses these skills, the chance is greater that the process is progressive. The technological revolution and progress in molecular genetics in the past 20 to 30 years provide greater avenues for the diagnosis of many of the progressive disorders affecting neurons and central nervous system (CNS) function. Many disorders can be diagnosed in utero, and treatments are available for some. It has become increasingly evident that many of the inherited neurodegenerative disorders have varied clinical phenotypes, and clinical phenotypes may overlap between some of the disorders. This article provides a framework for the primary physician to consider some of these disorders and a rational approach to the evaluation of a child suspected of having a progressive neurodegenerative disorder.
Neurodegenerative disorders can present at any age, with manifestations varying with the age of presentation. Tables 1 and 2 provide some of the clinical and laboratory features that may be seen in a neonate or child who has a progressive disorder. Certain historical and physical findings may indicate such disorders. Some of these disorders are referred to as lysosomal disorders because of the tendency to store breakdown products of normal substrates within the lysozyme. Categories of lysosomal disorders include the storage of mucopolysaccharides, lipids, glycogen, and oligosaccharides. Recent enzyme determinations show that the infantile and childhood forms of neuronal ceroid lipofucinoses also fit into this broad category. Clinical symptoms involve a variety of organ systems that may be reflected by bone abnormalities, organomegaly, CNS abnormalities, and coarseness of face and hair. A recent study from Australia reports the prevalence of lysosomal storage disorders for that continent as 1 per 7,700 live births (Meikle et al 1999) .
Lipidoses
These disorders are the result of inherited abnormalities of lipid metabolism and involve those lipids containing sphingosine, which is a primary component of the myelin and comprises about 16% of white matter. Lysosomal enzymes, frequently hydrolases, may be decreased, absent, or nonfunctional. This allows abnormal accumulation of the specific lipids within the CNS white matter. Enzyme levels down to 10% of normal may still result in a phenotypically normal individual. The lipidoses include: Niemann-Pick disease (disorder of sphingomyelin), Gaucher disease (disorder of glucosylceramide), Krabbe disease (disorder of galactosylceramide), metachromatic leukodystrophy (disorder of sulfatide), Tay-Sachs Disease (GM 2 gangliosidosis), and generalized gangliosidosis (GM 1 gangliosidosis) (Table 3 ). Within each one of these disorders are many phenotypes and ages of presentation.
Niemann-Pick Disease (Sphingomyelin Lipidosis)
This disease has four clinical types: A, B, C, and D. A recently described form in adults (type E) has storage of sphingomyelin, but no neurologic symptons. The lysosomal enzyme deficiency is sphingomyelinase. About 85% of the cases fall into the classic infantile form (type A). Types A, B, and C are associated with hepatosplenomegaly and "foam cells" (Niemann-Pick cells) in the liver and bone marrow. Type C presents in early childhood, between 2 to 4 years of age, and type D presents in later childhood. Types A, C, and D progress to death within 2 to 5 years of presentation. All have an autosomal recessive inheritance pattern.
The primary clinical features are hepatosplenomegaly, cognitive regression, macular degeneration with cherry-red spot in about 25% of cases, hypotonia, areflexia, and delayed nerve conduction velocities. Type B has visceral but no CNS involvement. Brain imaging with both computed tomography (CT) and magnetic resonance imaging (MRI) reveal brain atrophy with volume loss. The diagnosis is made by assay of the bone marrow or liver for foam cells and determination of sphingomyelinase levels in white blood cells for types A and B and fibroblasts for type C. Treatment is primarily supportive. Bone marrow transplant has been tried in a few cases, but without success.
Gaucher Disease (Glucosylceramide Lipidosis)
All three forms of Gaucher disease present with hepatosplenomegaly. The infantile and juvenile forms progress to an early death following regression in psychomotor skills and cognitive functioning. This disease is one of the most frequent lysosomal disorders and the most common among Ashkenazi Jews, in whom the prevalence is 1 per 855 (Meikle, 1999) . The enzyme defect is betaglucocerebrosidase; the defect leads to an accumulation of glucosylceramide in brain, liver, spleen, and bone marrow.
The infantile form of this disease presents within the first year of life, usually by 6 months of age. The infant is hyperextended, seemingly opisthotonic, and has an enlarged spleen and liver. Death occurs by 2 years in the infantile form and by early adolescence in the juvenile form. The adult form, which presents in the teen years, consists of visceromegaly and is associated with a long 
Krabbe Disease (Galactosylceramide Lipidosis)
This also has been called globoid cell leukodystrophy. There are two phenotypic forms of this lipidosis. One presents within the first 3 to 6 months of life and the other later in infancy or childhood. Inheritance is autosomal recessive, and the lysosomal enzyme defect is galactocerebrosidase. White blood cells, serum, and amniotic fluid are all sources for enzyme determination. Typically, affected infants present within the first 3 to 4 months of life with extreme irritability, fevers of unknown origin, and rigidity leading to feeding problems. Muscle stretch reflexes initially may be increased, but as the course progresses, they are lost. With disease progression, vision and hearing are lost. The child usually dies of intercurrent illnesses within the first 2 years of life. Brain imaging with both CT and MRI reveal significant white matter changes, primarily in the occipital and parietal lobes. T 2 changes in the centrum semiovale also have been reported.
Metachromatic Leukodystrophy (Sulfatide Lipidosis)
This lipidosis occurs because of deficiency of the lysosomal enzyme arylsulfatase A, a cerebroside sulfatase. There are three isoenzymes for arylsulfatase: A, B, and C. The A isoenzyme is decreased in the infantile, juvenile, and adult forms of metachromatic leukodystrophy. The genes for this enzyme have been mapped to chromosome 22, 22q13.31.
Clinical features typically develop within the first 2 years of life, but presentation may occur as late as 4 to 5 years. The initial presentation is a gait dysfunction, usually ataxia with or without weakness. There also is a prominent neuropathy, and the muscle stretch reflexes typically are decreased or absent. The course progresses rapidly over the next 1 to 2 years, with the development of spasticity, loss of intellectual skills, optic atrophy, and seizures. Some patients may have a cherry-red spot in the macula. The juvenile form develops around 5 to 10 years of age. The progression of the illness is similar to that of the infantile form. Affected children may live into their late teens or early 20s compared with death before the age of 10 years among those who have infantile-onset disease. An adult form can present in the third to fourth decade with psychosis, dementia, and progressive clinical signs of the spinocerebellar, corticospinal, and cerebellar systems. A motor neuron disease presentation has been described.
Pertinent laboratory studies include demonstration of absent or decreased enzyme in urine or leukocytes; ab- Like the other lysosomal disorders, metachromatic leukodystrophy is inherited as an autosomal recessive trait. Treatment to date has been primarily supportive. Some have reported a delay in disease progression after bone marrow transplantation. Recent research reveals 
Tay-Sachs Disease (GM 2 Gangliosidosis)
Tay-Sachs disease results from deficiency of the enzyme hexosaminidase A and subsequent storage of ganglioside within neurons of the CNS and autonomic and peripheral nervous systems. Children present in early infancy with increased sensitivity to noise (hyperacusis) and an increased startle response to noise. Development is delayed, as is vision; children who have developed some vision lose it and are usually blind by 1 year of age. The other characteristic feature is the cherry-red spot that represents loss of ganglion cells in the foveal area with the remaining ones filled with the ganglioside. Most infants also develop myoclonic seizures during the first year of life. Brain CT and MRI findings are abnormal. CT findings include areas of low density in the basal ganglia and cerebral white matter, and MRI changes include an increased signal in these same regions on T 2 -weighted images. Death occurs at 2 to 3 years of age, with some affected children living to 4 years. This disease is transmitted as an autosomal recessive trait, primarily in those of Ashkenazi Jewish descent. The carrier state for this population is 1 in 27. The gene locus for the enzyme is 15q23-q24. Prenatal screening can identify affected fetuses using amniotic fluid and chorionic villi for assay of the enzyme. Treatment to date has been primarily supportive. There has been some research using enzyme replacement therapy and bone marrow transplantation.
Sandoff disease is a variant of GM 2 gangliosidosis that results from deficiencies of both hexosaminidase A and B. Clinical symptoms are very similar to those of Tay-Sachs disease, including the cherry-red spot. Affected infants die within the first 2 to 3 years of life. It is possible to diagnose carriers and fetuses. Treatment options are similar to those for Tay-Sachs disease.
Generalized Gangliosidosis (GM 1 Gangliosidosis)
Brain and other organs are involved with this lipidosis. Neurons store GM 1 ganglioside because of deficiencies in beta-galactosidase and asialoganglioside (neuraminic acid). Mucopolysaccharides, in the form of keratan sulfates, also are stored in the liver and spleen. Three clinical forms are recognized: infantile, juvenile, and chronic. Clinically, affected infants demonstrate coarse facial features at birth; edema of the face, hands, and feet; frontal bossing; a dull look; and prominent hepatosplenomegaly. They often are misdiagnosed as having a muco-polysaccharidosis. Bony abnormalities of dyostosis multiplex, with kyphoscoliosis, beaking of vertebrae, and shortened fingers and toes, become more evident as the children age. Disease progression is characterized by the development of seizures, blindness, deafness, and death by 2 years of age. The progression is slower in the juvenile and adult forms. In the latter, visceral and bone storage does not occur. Brain imaging abnormalities have been noted on both CT and MRI. These changes are often nonspecific, with diffuse atrophy, although high-intensity signals have been reported in the basal ganglia on T 2 -weighted MRI. Inheritance is autosomal recessive. Diagnosis can be established by identifying the absence of the enzyme beta-galactosidase in white blood cells, fibroblasts, and cultured amniocytes. Treatment is supportive.
Neuronal Ceroid Lipidoses
This group of disorders has been grouped with the lipid storage diseases because storage material was found in neurons that absorbed lipid stains and resembled lipofuscin. Earlier classification systems identified four main types, based on age at presentation and the ultrastructure of the stored material. However, there was not always a clear-cut association between these two features. Current classification recognizes six different clinical syndromes. Chromosomal linkage is known for five of the syndromes, and specific genes have been mapped for four. The six clinical groups are: infantile (Santavuori-Haltia), late infantile (Jansky-Bielschowsky), juvenile (Spielmeyer-Vogt-Sjögren or Batten), adult (Kufs), Finnish late infantile, and Finnish early juvenile.
The infantile form presents between 8 and 18 months of age. Affected infants often exhibit microcephaly and myoclonic seizures. There is visual impairment, with optic atrophy, narrowing of the retinal vessels, and some macular changes. The children progressively lose developmental skills, reaching a vegetative state and death by about 10 years of age. Inclusions of autofluorescent lipofuscin (saposin) are found not only in neurons but in other organs of the body, including thyroid, pancreas, kidneys, testes, and smooth and skeletal muscle. The ultrastructure of the lipopigment on skin biopsy shows granular osmophilic deposits.
The late infantile form (Jansky-Bielschowsky) presents between 2 and 4 years of age with seizures (both myoclonic and convulsive), ataxia, basal ganglia dysfunction, progressive mental and motor deterioration, and visual loss. The visual impairment occurs late in the disease course. The disease is progressive, with death occurring between 8 and 15 years of age. The electro-neurology degenerative CNS disease retinogram (ERG) is unusually small or absent later in the course of the disease. Electroencephalography demonstrates an exaggerated response to photic stimulation, and background patterns become increasingly slow and less well-regulated. Inclusions of the lipofuscin pigment are detected as curvilinear bodies in various tissues, including neurons, hepatocytes, and bone marrow. The gene for this form (LINCL) has been mapped to a lyosomal pepstatin-insensitive peptidase on chromosome 11p15. Prenatal detection of this gene has been reported using DNA and enzyme-based methods on amniocytes. Treatment remains supportive. Seizures are difficult to treat and often unresponsive to antiepileptic medications.
The juvenile form (Spielmeyer-Vogt-Sjögren) presents with early visual loss and later seizures and dementia. Onset usually is between 5 and 10 years of age. As with the earlier forms, the disease is progressive, with death occurring in the teens and 20s. The gene for this disorder (LINCL3) codes for the lysomal enzyme adenosine triphosphate synthase on chromosome 16p12. The ultrastructure of the stored lipofuscin is that of a fingerprint.
There are adult forms of this disorder and other variants referred to as the Finnish type. The chromosome for the adult variant is not yet known, and the Finnish forms code to chromosome 13q31-32. Laboratory results that may be helpful include the ERG if decreased or absent, presence of dolichols in the urine, and retinal deterioration with small vessels. Inheritance is autosomal recessive.
Carbohydrate-deficient Glycoprotein Syndromes
Diseases in this category (Table 3) occur as deficiencies involving the endoplasmic reticulum and the Golgi ap-paratus. These cellular structures are involved in protein translation and modification with sugar molecules (endoplasmic reticulum) and importation of the proteins with further modification (Golgi apparatus). It is here that oligosaccharides are added to some of the glycoproteins. A number of different phenotypes are recognized, but the most frequently recognized is type 1a (phosphomannomutase deficiency). Clinically, affected children may present with life-threatening illnesses in infancy that could include heart, liver, or other organ failure. There is cerebellar hypoplasia, cataracts, history of hypoglycemia, protein-losing enteropathy, stroke-like episodes, seizures, retinopathy, and recurrent infections. Measurement of glycoproteins antithrombin III and thyroidbinding globulin may indicate deficiencies in this group of glycoproteins. A reliable laboratory test is the measurement of the abnormal transferrin isoform by immunoisoelectric focusing. Many affected children die in early childhood from intercurrent illnesses. The disease may stabilize in later childhood; a severe peripheral neuropathy then may develop. Some children survive to adulthood with disproportionately long limbs and short trunk, ataxia, and mental retardation.
Peroxisomal Disorders
Peroxisomes are membrane-bound organelles that play important roles in multiple catabolic and synthetic metabolic functions. Some of these include beta-oxidation of fatty acids, alpha-oxidation of branched-chain fatty acids, pipecolic acid degradation, and plasmalogen ether lipid and bile acid synthesis. Diseases related to the dysfunction of these organelles were first noted in 1973 when they were found to be missing in Zellweger syndrome. Diseases occurring as a result of peroxisome dysfunction fit into one of three categories: 1) disorder of biogenesis with decreased numbers of peroxisomes or misshapen peroxisomes; 2) multiple syndromes with single enzyme defects; and 3) impaired peroxisomal function with intact peroxisomes. These organelles play significant roles in neuronal migration, the metabolism of cholesterol and polyunsaturated fats, and prostaglandins. Examples of Group I peroxisomal disorders include Zellweger syndrome, neonatal adrenoleukodystrophy, and infantile Refsum disease (Table 4 ). Naidu and associates have noted the phenotypic and genotypic variabil-. . . psychomotor retardation, dysmorphia, hypotonia, hepatomegaly, seizures, retinal pigmentation or absent ERG, sensorineural hearing loss, renal cysts, aberrant calcific stippling, and adrenal insufficiency are indicative of Group I peroxisomal disorders . . . neurology degenerative CNS disease ity of this group. Certain physical findings suggest this group of disorders, including psychomotor retardation, dysmorphic features, hypotonia, hepatomegaly, seizures, retinal pigmentation or absent ERG, sensorineural hearing loss, renal cysts, aberrant calcific stippling, and adrenal insufficiency (Table 3 ). Theil reported that more than 75% of patients have at least three major features.
Group II peroxisomal disorders include childhood X-linked adrenoleukodystrophy, adrenomyeloleukodystrophy, and classic Refsum disease. Most patients who have disorders in this group have elevations in plasma very long-chain fatty acids (VLCFAs). Some also may have elevated bile acid intermediates. The most common form of this group is the X-linked adrenoleukodystrophy that presents in males during childhood (4 to 8 years). Affected children often present with progressive deterioration in schoolwork, auditory discrimination and speech problems, and sometimes seizures. Brain MRI shows distinctive white matter changes in the parieto-occipital region in about 85% of cases and in the frontal regions in 15% of cases. A common presentation is Addison disease without a CNS abnormality.
Rhizomelic chondroplasia punctata is the major disorder in Group III peroxisomal disorders. Peroxisomes are intact, but there is dysfunction of more than one peroxisomal enzyme. Typical clinical features include shortening of the proximal portion of upper and lower extremities, microcephaly, ichthyosis, cataracts, and severe mental retardation. The striking feature is the radiographic appearance of epiphyseal stippling in the knees, hips, elbows, and shoulders.
The biochemical defects common to the disorders of peroxisomal biogenesis include elevation of VLCFAs, increased plasma phytanic acid, decreased plasma erythrocyte plasmalogen lipids, increased abnormal bile acid intermediates, and deficient docosahexaenoic acid ( Table 4 ). Measurements of these chemicals usually cannot distinguish the different forms of peroxisomal disorders.
Prenatal screening is possible for several of the disorders. All of the Group I disorders can be diagnosed by measuring VLCFAs and plasmalogen synthesis in cultured amniocytes and chorionic villus cells. Peroxisomal structure also can be assessed using cultured amniocytes and chorionic villus samples. Isolated acyl-CoA oxidase deficiency with elevated VLCFAs and normal bile acid intermediates have been reported in amniotic fluid; deficient alanine cyloxylate aminotransferase in fetal liver biopsy; classic Refsum disease via elevations in phytanic acid in cultured amniocytes or chorionic villus samples; and rhizomelic chondrodysplasia punctata on fetal ultrasonography.
Therapies for these disorders are much less precise and effective. For the group I disorders, treatment is primarily supportive, with referral to programs for occupational, physical, and speech therapy. Medical therapies include treatment of liver dysfunction with vitamin K. Dietary manipulation of the VLCFAs has not been shown to alter the disease course. Use of ursodeoxycholic acid may decrease some of the bile acid intermediates, thereby preventing some liver damage. There has been much more publicity about the treatment for the group II disorders (eg, X-linked adrenoleukodystropy). Trials of dietary restriction of VLCFAs have not documented alterations in their plasma levels or the clinical course of the disease. Bone marrow transplantation has been performed in individuals who are diagnosed early in the disease course and who do not yet have significant involvement. Treatment for group III disorders (rhizomelic chondrodysplasia punctata) is primarily supportive, with the addition of dietary restriction of phytanic acid.
Mitochondrial Disorders
Disorders involving the mitochondrion have many phenotypes. These diseases involve disorders of oxidative Specific mitochondrial syndromes are mitochondrial myopathy, encephalopathy, lactic acidosis and strokelike episodes (MELAS); myoclonus epilepsy with ragged-red fibers (MERRF); Kearns-Sayre syndrome (KSS), characterized by progressive external ophthalmoplegia, pigmentary degeneration of the retina, and heart block, cerebellar syndrome, or elevated CSF protein; and Leigh syndrome (LS).
Symptoms of mitochondrial disorders involve many systems of the body because multiple tissues are affected by these disorders of oxidative metabolism (Table 5 ). These include apnea or other respiratory abnormalities, cardiomyopathy, hypotonia, ophthalmoplegia, acute life-threatening event, myoclonic seizures, paroxysmal vomiting, sensorineural hearing loss, thyroid disease, migraine, and pancreatitis.
When the clinical history suggests a mitochondrial disorder, certain laboratory studies may be helpful in the diagnosis, including serum lactate and pyruvate (blood should be free-flowing, placed on ice, and sent to the laboratory) and CSF lactate and pyruvate. The latter may be more accurate than serum values and frequently is abnormal when the corresponding serum value is normal. Other important studies include measurement of serum glucose; a serum carnitine profile that includes total, free, and acylcarnitine levels; and evaluation of urine organic acids, serum amino acids, and serum ammonia. Biopsies of liver and muscle may be necessary in some instances. In some disorders of lactic acidemia, examination of muscle tissue using a Gomori trichome stain may show a pattern referred to as "ragged red fibers," which represent aggregates of mitochondria. Electron microscopic examination of muscle tissue also may reveal other abnormalities of mitochondrial structure, size, and number. Certain laboratories throughout the United States can assay frozen muscle tissue for some of the specific respiratory enzyme complexes I to IV, but freshly isolated mitochondria provide better material for study. Liver biopsies are useful in diagnosing disorders of beta-oxidation.
Neuroimaging with MRI is an important and useful tool in the diagnosis of mitochondrial disorders. One acute change during a metabolic crisis may be diffuse cerebral edema. Bilaterally increased signals in the putamen, caudate nucleus, and globus pallidus are often seen in LS. Calcification of the basal ganglia is seen in MELAS and KSS. Patients who have MELAS may have lesions in the posterior cerebrum that appear as strokes. Agenesis of the corpus callosum has been reported with pyruvate dehyrogenase deficiency.
Genetic testing for some of the most common mutations of the mitochondrion (MELAS, MERRF, Leber optic atrophy, KSS) can be performed using blood samples. In some of the other disorders involving a single deletion, muscle tissue may be better for the DNA analysis.
Treatment
Therapy to date for these degenerative disorders has been limited and not very successful. The goals have been to correct the metabolic abnormalities such as lactic acidosis, remove toxic metabolites, and treat cardiac irregularities and other life-threatening conditions. Specific treatment regimens include the use of biotin in biotinidase deficiency; folic acid supplementation in Kearn-Sayre syndrome; L-carnitine in carnitine deficient syndromes; coenzyme Q and B complex multivitains in mitochondrial disorders; and the ketogenic diet with mediumchain triglyceride oil, thiamine, and lipoic acid in disorders of the pyruvate dehydrogenase complex. Treatment of lactic acidosis has not been successful; the use of sodium bicarbonate sometimes worsens the associated cerebral edema. Dichloroacetate may be more effective, but its use is still experimental. Other therapies include cardiac pacemakers for those who have cardiac rhythm disorders as in Kearn-Sayre syndrome and adequate caloric supplementation.
